Mr. Peter Lin brings over 20 years of diverse strategic, investment, and executive leadership experience to Apollomics. He previously served as Chief Financial Officer at Tanvex Biopharma, Tanvex CDMO, Tanvex Biopharma USA, and Tanvex Biologic Corporation (Taiwan). Before his tenure at Tanvex, Mr. Lin was Chief Financial Officer of Theragent, a start-up CDMO specializing in gene and cell therapy.

Mr. Lin’s background also includes significant expertise in investment management. As a Principal and Investment Manager at Solarium Capital, a boutique private equity fund, he executed acquisitions and equity investments across technology, food and beverage, and real estate sectors. Earlier in his career, following his MBA, he joined WesCorp as an Investment Research Manager, where he led a credit research team overseeing a $32 billion fixed-income portfolio, one of the world’s largest structured credit portfolios. His team analyzed and managed investments in U.S. and global structured finance products, including MBS, ABS, CDOs, esoteric ABS, and corporate debt securities.

Beyond his executive roles, Mr. Lin serves as a board member for companies across the biopharma, medical device, media, publishing, and real estate private equity sectors.

Mr. Lin holds a B.A. in Business Administration from the University of California, Berkeley, a Master’s degree in Information Systems from Claremont Graduate University, and an International Business Education and Research MBA from the University of Southern California (USC). He is also a Chartered Alternative Investment Analyst (CAIA) charterholder.